North America Dominated the Osteoporosis Drugs Industry

The size of the osteoporosis drugs market will power at a compound annual growth rate of 5.2% during 2022-2030, to touch a value of USD 22,947 million by 2030.

This growth of the industry is due to increasing healthcare expenditure, the high prevalence of osteoporosis and the speedy urbanization affecting bone health.

India is one of the fastest growing markets for osteoporosis drugs due to deteriorating health of women as a result of morbid lifestyle. Surging number of women suffering from osteoporosis resulted in reduced bone mass and altered bone structure.

Osteoporosis has become a major health issue as about 50 million out of 230 million Indians were women aged over 50 and were suffering from osteoporosis.

The widespread prevalence of this disease is due to low calcium intake, along with vitamin D deficiency, increased life expectancy, sex inequity, early menopause, hereditary predisposition, absence of diagnostic tools, and lack of awareness regarding bone health.

There has been a significant surge in the awareness regarding osteoporosis globally as a result of many initiatives taken by the governments and private associations in the form of multiple programs and campaigns.

Healthcare expenditure is surging globally because of the increasing prevalence of diseases and increasing government and non-government initiatives. This leads to advancement in healthcare infrastructure and increasing affordability and accessibility of diagnosis and treatment for many medical conditions.

The bisphosphonates category marked the largest revenue share of around 30% in the past. Bisphosphonates bind with the surface of the bone’s mineral and effectively block osteoclast-mediated bone resorption. They then embed in the bone and are only released after subsequent resorption resulting in slower rate of bone resorption.

The RANK ligand inhibitor category will grow at highest CAGR in the near future. An advance therapeutic target has been discovered with the identification of receptor activator of nuclear factor-B ligand (RSANKL) as an important regulator of osteoclast process.

Osteoclast genesis is triggered by RANKL, but it is inhibited by OPG. Denosumab, a RANKL-neutralizing antibody help in strengthening bones in osteoporosis patients. RANKL improve limb force proportionally in order to increase muscle mass.

Primary osteoporosis is most likely to affect women after menopause due to the sudden decrease in estragon production. Sudden and disproportionate loss of trabecular bone takes place in this condition. Further, wrist, hip and spine fractures are also caused as a result of this.

Demand for injectable osteoporosis drugs will grow at highest CAGR. This is due to beneficial features of intravenous drugs like, they do not upset the stomach and it is easier for some individuals to get quarterly or yearly infusion than to take a weekly or monthly pill.

The osteoporosis drugs market was dominated by North America with a share of around 45%. This is owing to surging geriatric population, increasing cases of obesity, surging lifestyle-related diseases and rising prevalence of osteoporosis.

It is because of the surging prevalence of osteoporosis, increasing requirement for RANK ligand inhibitor, growing demand for injectable drugs and government support, the demand for osteoporosis drugs will continue to rise in the years to come.